Research programme: dipiperidine anti-infectives/anti-inflammatories - Sequella
Alternative Names: SQ 609Latest Information Update: 04 Nov 2017
At a glance
- Originator Sequella
- Class Adamantanes; Piperidines; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Crohn's disease; Severe acute respiratory syndrome; Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in USA (PO)
- 24 Sep 2012 SQ 609 is available for licensing as of 24 Sep 2012. http://www.sequella.com/
- 12 Sep 2012 SQ 609 is still in Preclinical trials for Tuberculosis in USA